Dr. Marcusson is a scientific leader with over 25 years of experience and deep expertise in antisense oligonucleotide (ASO) drug discovery and development. At Isis Pharmaceuticals (now Ionis), he led preclinical teams that advanced multiple ASO oncology programs into the clinic. Dr. Marcusson later co-founded Regulus Therapeutics, helping to build one of the first biotechnology companies dedicated to microRNA-based therapeutics and contributing to its successful IPO. He currently serves as Co-founder, Board Member and Chair of the Scientific Advisory Board at Providence Therapeutics and has his own consultancy firm. His work spans ASOs, microRNA therapeutics, siRNA, and other RNA-targeting modalities across drug discovery, target validation, functional genomics, and preclinical development. At iNFixion Bioscience, he contributes deep expertise in ASO design and preclinical strategies to help accelerate the development of therapies for people with NF1.